Advertisement
YOU ARE HERE: LAT HomeCollectionsScripps Research Institute
IN THE NEWS

Scripps Research Institute

FEATURED ARTICLES
CALIFORNIA | LOCAL
April 19, 1990 | LINDA ROACH MONROE, TIMES STAFF WRITER
A drug developed at Scripps Research Institute has shown near-total effectiveness against a rare form of leukemia without the debilitating side effects that usually accompany cancer therapy, San Diego researchers say. Reporting in today's issue of the New England Journal of Medicine, the Scripps scientists were careful to point out that the cancer they studied, hairy-cell leukemia, is diagnosed in only 500 to 600 people a year in the United States.
ARTICLES BY DATE
SCIENCE
October 31, 2013 | By Geoffrey Mohan
The search for an HIV vaccine has taken an important step forward after researchers at the Scripps Research Institute in La Jolla managed to capture molecular images of a protein spike that allows the deadly virus to invade human immune cells to hack their genetic code. The ability to control and analyze that shape-shifting envelope trimer protein, which has evaded the best efforts of biochemistry for more than a decade, could offer researchers the ability to see whether they can induce natural antibodies to attack the virus' most vulnerable spot, a crucial step toward engineering a vaccine.
Advertisement
CALIFORNIA | LOCAL
February 10, 2008 | Thomas H. Maugh II, Times Staff Writer
Dr. Frank Dixon, an immunologist who pioneered the use of radiolabeling in molecular biology, who was among the first to explain how autoimmune diseases worked and who founded the Scripps Research Institute in La Jolla, died Friday at his home in the San Diego community of La Jolla Shores. He was 87. Dixon had been suffering from aortic stenosis and apparently died of heart failure in his sleep, according to Scripps spokesman Keith McKeown.
SCIENCE
September 12, 2013 | By Geoffrey Mohan
Researchers seeking weapons against HIV have solved a molecular riddle about how the pathogen docks with immune system cells to unleash its viral mayhem. Their computer-generated images of the molecules, which are 185,000 times smaller than the width of a human hair, offer researchers promising avenues for developing a drug that might impede HIV's cellular invasion, according to a study published online Thursday in the journal Science Express. “We don't have the whole scenario of what happens when HIV enters a cell, but this is going to be a major jigsaw-puzzle piece,” said Dr. P.J. Klasse, a virologist at Weill Cornell Medical College in New York, who was not part of the research team.
NEWS
October 5, 1991 | NORA ZAMICHOW, TIMES STAFF WRITER
In a move that signals San Diego's maturation as a heavyweight in scientific circles, a prestigious New York City brain research center announced Friday that it will relocate here. The Neurosciences Institute, an independent center based at Rockefeller University, will move to the Scripps Research Institute, where a building will be constructed to house the team. Dr. Gerald Edelman, director of NSI, won the Nobel Prize in 1972 for his research on the chemical structure of antibody molecules.
CALIFORNIA | LOCAL
August 3, 1991 | NORA ZAMICHOW, TIMES STAFF WRITER
A prestigious national foundation granted $6.5 million to two San Diego research institutions, officials announced Friday. The Scripps Research Institute received a $5-million gift, its largest ever from a private foundation, to research how cells function, which the institute believes could lead to disease-resistant crops and drugs to combat heart disease and cancer. And the La Jolla Cancer Research Foundation received $1.5 million to study how cancer-causing cells travel through the body.
BUSINESS
December 4, 1992 | From Times Staff and Wire Reports
Scripps Institute, Big Drug Maker Link Up: In one of the largest deals of its kind, giant Sandoz Pharmaceuticals Corp. has agreed to give La Jolla-based Scripps Research Institute $300 million in return for right of first refusal to Scripps' future medical discoveries. New Jersey-based Sandoz will provide the research funding over a 10-year period beginning in 1997.
BUSINESS
July 7, 1993 | From Times Staff and Wire Reports
Scripps Altering Its Deal With Sandoz: The nation's largest independent biomedical research institute said it is reworking a contract with the pharmaceutical company to reduce the control the Swiss drug maker will have over the research center. La Jolla-based Scripps announced the change after its proposed affiliation with Sandoz was attacked in congressional hearings as amounting to a foreign buyout.
NEWS
February 11, 1994 | Reuters
San Diego researchers reported Thursday that they had achieved complete chemical synthesis of taxol, a promising anti-cancer drug made from the yew tree. The research by the team of scientists from Scripps Research Institute in La Jolla will be published in the Feb. 17 issue of the magazine Nature. Taxol was originally isolated from the Pacific yew tree. More recently it has also been made from the European yew.
SCIENCE
April 25, 2009 | Times Staff and Wire Reports
Researchers have developed a way to make embryonic-like stem cells by soaking skin cells in genetically engineered proteins, a new step toward using ordinary cells to treat disease. An international team led by Scripps Research Institute in California said Thursday that this was the safest method yet found to transform ordinary skin cells into what are called induced pluripotent stem cells, or iPS cells. They reported their findings -- from research using mouse cells -- in the journal Cell Stem Cell.
SCIENCE
April 25, 2009 | Times Staff and Wire Reports
Researchers have developed a way to make embryonic-like stem cells by soaking skin cells in genetically engineered proteins, a new step toward using ordinary cells to treat disease. An international team led by Scripps Research Institute in California said Thursday that this was the safest method yet found to transform ordinary skin cells into what are called induced pluripotent stem cells, or iPS cells. They reported their findings -- from research using mouse cells -- in the journal Cell Stem Cell.
CALIFORNIA | LOCAL
February 10, 2008 | Thomas H. Maugh II, Times Staff Writer
Dr. Frank Dixon, an immunologist who pioneered the use of radiolabeling in molecular biology, who was among the first to explain how autoimmune diseases worked and who founded the Scripps Research Institute in La Jolla, died Friday at his home in the San Diego community of La Jolla Shores. He was 87. Dixon had been suffering from aortic stenosis and apparently died of heart failure in his sleep, according to Scripps spokesman Keith McKeown.
CALIFORNIA | LOCAL
December 8, 2000 | KENNETH R. WEISS and JEFF GOTTLIEB, TIMES STAFF WRITERS
Gov. Gray Davis on Thursday awarded $300 million to three new University of California research institutes--including a joint UC Irvine/UC San Diego project on telecommunications--that will expand the frontiers of science and technology. "It's hard to contain my enthusiasm for what the governor has done here," said Bill Parker, UCI associate vice chancellor. "It's probably the most significant event in the history of the campus in advancing the research mission in one step."
NEWS
February 11, 1994 | Reuters
San Diego researchers reported Thursday that they had achieved complete chemical synthesis of taxol, a promising anti-cancer drug made from the yew tree. The research by the team of scientists from Scripps Research Institute in La Jolla will be published in the Feb. 17 issue of the magazine Nature. Taxol was originally isolated from the Pacific yew tree. More recently it has also been made from the European yew.
BUSINESS
December 22, 1993 | CHRIS KRAUL, TIMES STAFF WRITER
The Scripps Research Institute said it will discontinue a controversial stock awards program after government critics charged that it posed a potential conflict of interest in the licensing of Scripps' government-sponsored research to private companies. The stock controversy stems from Scripps' practice of distributing to some employees a portion of stock it receives as payment for its technology.
BUSINESS
July 7, 1993 | From Times Staff and Wire Reports
Scripps Altering Its Deal With Sandoz: The nation's largest independent biomedical research institute said it is reworking a contract with the pharmaceutical company to reduce the control the Swiss drug maker will have over the research center. La Jolla-based Scripps announced the change after its proposed affiliation with Sandoz was attacked in congressional hearings as amounting to a foreign buyout.
CALIFORNIA | LOCAL
December 4, 1992 | GREG JOHNSON, TIMES STAFF WRITER
In one of the largest deals of its kind, Sandoz Pharmaceuticals Corp. has agreed to give La Jolla-based Scripps Research Institute $300 million in return for right of first refusal to Scripps' future medical discoveries. According to terms of the deal announced Thursday by Sandoz, the giant, New Jersey-based drug company will provide $300 million in research funding over a 10-year period beginning in 1997.
BUSINESS
September 24, 1991
Baxter Healthcare Corp. said it asked a federal court to dismiss a patent-infringement claim against one of its drugs that helps stop bleeding in hemophiliacs. The drug is manufactured by Baxter's Hyland division in Glendale. The U.S. patent in question is held by The Scripps Research Institute and is licensed to a French pharmaceutical company, Rhone-Poulenc Rorer Inc., which filed a motion Sept. 12 to stop Baxter Healthcare from selling its version of the drug.
BUSINESS
June 18, 1993 | ROBERT A. ROSENBLATT, TIMES STAFF WRITER
The federal government, angered by the Scripps Research Institute's proposed marketing agreement with a giant Swiss pharmaceutical company, is threatening to take away from Scripps the exclusive rights to patents from its biotechnology discoveries, the director of the National Institutes of Health told Congress on Thursday. In unusually strong language, Dr.
BUSINESS
March 22, 1993 | CHRIS KRAUL, TIMES STAFF WRITER
When Scripps Research Institute signed a 10-year, $300-million research agreement in December that gives Swiss pharmaceutical giant Sandoz first rights on all technology developed at the La Jolla facility, neither party anticipated the firestorm that was to erupt. Scripps seemed to be in line with other research laboratories--whether university-run or private--that have increasingly collaborated with the corporate world to make up for growing costs and a scarcity of government funding.
Los Angeles Times Articles
|